Nextcell Pharma Ab Stock Fundamentals
| NXTCL Stock | SEK 1.69 0.01 0.60% |
NextCell Pharma AB fundamentals help investors to digest information that contributes to NextCell Pharma's financial success or failures. It also enables traders to predict the movement of NextCell Stock. The fundamental analysis module provides a way to measure NextCell Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NextCell Pharma stock.
NextCell |
NextCell Pharma AB Company Return On Equity Analysis
NextCell Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current NextCell Pharma Return On Equity | -0.3 |
Most of NextCell Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NextCell Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, NextCell Pharma AB has a Return On Equity of -0.2957. This is 98.77% lower than that of the Healthcare sector and 99.19% lower than that of the Biotechnology industry. The return on equity for all Sweden stocks is 4.61% lower than that of the firm.
NextCell Pharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NextCell Pharma's current stock value. Our valuation model uses many indicators to compare NextCell Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NextCell Pharma competition to find correlations between indicators driving NextCell Pharma's intrinsic value. More Info.NextCell Pharma AB is regarded second in return on equity category among its peers. It also is regarded second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NextCell Pharma's earnings, one of the primary drivers of an investment's value.NextCell Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NextCell Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NextCell Pharma could also be used in its relative valuation, which is a method of valuing NextCell Pharma by comparing valuation metrics of similar companies.NextCell Pharma is currently under evaluation in return on equity category among its peers.
NextCell Fundamentals
| Return On Equity | -0.3 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (4.75) % | |||
| Current Valuation | 134.94 M | |||
| Shares Outstanding | 34.38 M | |||
| Shares Owned By Insiders | 42.82 % | |||
| Shares Owned By Institutions | 5.27 % | |||
| Price To Book | 2.01 X | |||
| Price To Sales | 37.14 X | |||
| Revenue | 5.59 M | |||
| Gross Profit | (2.49 M) | |||
| EBITDA | (34.08 M) | |||
| Net Income | (35.02 M) | |||
| Cash And Equivalents | 150.75 M | |||
| Cash Per Share | 4.39 X | |||
| Current Ratio | 42.29 X | |||
| Book Value Per Share | 3.10 X | |||
| Cash Flow From Operations | (33.31 M) | |||
| Earnings Per Share | (0.81) X | |||
| Number Of Employees | 15 | |||
| Beta | 0.43 | |||
| Market Capitalization | 255.91 M | |||
| Total Asset | 124.66 M | |||
| Net Asset | 124.66 M |
About NextCell Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NextCell Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NextCell Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NextCell Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden. NextCell Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 10 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.